Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
OwnerAprile Pilon, Anil Mukherjee +1inventors
InventorsAprile Pilon, Anil Mukherjee, Zhongjian Zhang
Life of this patent
Estimating the term…
Abstract
Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.
Claims21
1-32. (canceled)
A method for treating a fibrotic condition characterized by deposition of fibronectin, said method comprising administering native or recombinant uteroglobin to a patient in need of such treatment, wherein said fibrotic condition is cystic fibrosis.
A method for preventing a fibrotic condition characterized by deposition of fibronectin, said method comprising administering a compensating amount of native or recombinant uteroglobin to a patient in need of such treatment, wherein said fibrotic condition is cystic fibrosis.
46 The method of claim 42, wherein said UG is recombinant (rhUG) and has the same sequence as native human uteroglobin.
Dependencies are inferred from the claim text.